HC Wainwright Reaffirms "Buy" Rating for Celldex Therapeutics (NASDAQ:CLDX)

Celldex Therapeutics (NASDAQ:CLDX - Get Free Report)'s stock had its "buy" rating reaffirmed by analysts at HC Wainwright in a report issued on Friday,Benzinga reports. They currently have a $50.00 price objective on the biopharmaceutical company's stock. HC Wainwright's price objective would indicate a potential upside of 135.18% from the company's current price.

Other equities analysts have also issued reports about the company. UBS Group cut their target price on Celldex Therapeutics from $44.00 to $38.00 and set a "buy" rating on the stock in a research report on Friday, May 9th. Canaccord Genuity Group assumed coverage on Celldex Therapeutics in a research report on Monday, April 28th. They set a "buy" rating and a $64.00 price target for the company. Morgan Stanley dropped their price target on shares of Celldex Therapeutics from $46.00 to $43.00 and set an "overweight" rating on the stock in a research report on Friday, May 9th. Finally, The Goldman Sachs Group decreased their target price on shares of Celldex Therapeutics from $36.00 to $31.00 and set a "neutral" rating for the company in a report on Friday, May 9th. Two investment analysts have rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $50.90.

Celldex Therapeutics Price Performance

NASDAQ CLDX traded up $0.91 on Friday, hitting $21.26. 2,775,996 shares of the company's stock were exchanged, compared to its average volume of 936,371. Celldex Therapeutics has a fifty-two week low of $14.40 and a fifty-two week high of $47.00. The firm's 50-day moving average price is $19.31 and its two-hundred day moving average price is $21.83. The firm has a market cap of $1.41 billion, a price-to-earnings ratio of -8.27 and a beta of 1.33.

Celldex Therapeutics (NASDAQ:CLDX - Get Free Report) last posted its quarterly earnings data on Thursday, May 8th. The biopharmaceutical company reported ($0.81) EPS for the quarter, missing analysts' consensus estimates of ($0.75) by ($0.06). The company had revenue of $0.70 million for the quarter, compared to analysts' expectations of $1.08 million. Celldex Therapeutics had a negative return on equity of 19.75% and a negative net margin of 1,544.32%. On average, research analysts predict that Celldex Therapeutics will post -2.48 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Celldex Therapeutics

Several institutional investors have recently added to or reduced their stakes in the stock. EverSource Wealth Advisors LLC grew its position in shares of Celldex Therapeutics by 215.7% in the fourth quarter. EverSource Wealth Advisors LLC now owns 1,285 shares of the biopharmaceutical company's stock valued at $32,000 after purchasing an additional 878 shares in the last quarter. GAMMA Investing LLC boosted its stake in shares of Celldex Therapeutics by 6,665.9% in the 1st quarter. GAMMA Investing LLC now owns 2,977 shares of the biopharmaceutical company's stock valued at $54,000 after purchasing an additional 2,933 shares in the last quarter. Headlands Technologies LLC bought a new position in shares of Celldex Therapeutics during the fourth quarter valued at about $81,000. AlphaQuest LLC increased its stake in Celldex Therapeutics by 171.0% in the 4th quarter. AlphaQuest LLC now owns 4,287 shares of the biopharmaceutical company's stock worth $108,000 after purchasing an additional 2,705 shares during the period. Finally, Aquatic Capital Management LLC purchased a new stake in Celldex Therapeutics during the 4th quarter valued at $121,000.

About Celldex Therapeutics

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.